Morgan Stanley maintains Universal Health Services stock rating

Morgan Stanley reiterated an Equalweight rating on Universal Health Services (UHS) with a $200 price target following a discussion with the CFO, noting the company's strong financial health and potential for a catch-up trade given its underperformance relative to peers. While UHS beat EPS estimates in Q1 2025 ($4.80 vs. $4.36 forecast), it missed on revenue ($4.1B vs. $4.16B expected) but maintained its full-year earnings guidance and declared a $0.20 quarterly dividend. Analysts are monitoring volume trends in the behavioral segment and policy outcomes, as the stock currently trades at an attractive P/E ratio of 10.2.

Analysis

Morgan Stanley has reiterated an Equalweight rating on Universal Health Services (UHS) with a $200.00 price target, following a discussion with CFO Steve Filton. UHS, currently valued at $12.2 billion, reported a 9.7% revenue growth over the last twelve months. For Q1 2025, the company exceeded earnings expectations with an EPS of $4.80 against a $4.36 forecast, though revenue of $4.1 billion fell slightly short of the $4.16 billion anticipated. Despite this revenue miss, UHS maintained its full-year earnings guidance and reported a 21% increase in EBITDA for the quarter. The CFO highlighted solid acute care utilization and price-driven growth in the behavioral sector. InvestingPro assigns UHS a "GREAT" overall financial health score, noting strong profitability and 23 consecutive years of dividend payments, with a recent quarterly dividend of $0.20 per share declared. Management is also actively pursuing share buybacks. Morgan Stanley observes that UHS trades at an attractive P/E ratio of 10.2 and toward the lower end of its valuation range, with InvestingPro analysis suggesting undervaluation. The stock has underperformed its peers, presenting a potential catch-up opportunity, especially as policy impacts appear less severe than previously anticipated. Key factors for future performance include behavioral segment volume trends and policy outcomes. Cantor Fitzgerald also holds a Neutral rating with a $227.00 price target, citing staffing challenges but improvements in inpatient psychiatric care.

Key Decisions for Investors

• Investors might consider the current valuation attractive, given the P/E ratio of 10.2 and UHS's underperformance relative to peers, which could signal a potential catch-up trade.
• Closely monitor volume trends in the behavioral health segment and any policy changes affecting the healthcare sector, as these are identified as key catalysts for UHS's future performance.
• Given the maintained full-year guidance, consistent dividend payments, share buyback program, and strong financial health score, investors with a longer-term horizon could view the stock as a hold or consider accumulating on weakness, while acknowledging the current Equalweight/Neutral analyst consensus.